Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
33.58B
Market cap33.58B
Price-Earnings ratio
-102.81
Price-Earnings ratio-102.81
Dividend yield
Dividend yield
Average volume
1.35M
Average volume1.35M
High today
$255.38
High today$255.38
Low today
$234.04
Low today$234.04
Open price
$235.00
Open price$235.00
Volume
1.42M
Volume1.42M
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

The current Natera(NTRA) stock price is $245.38, with a market capitalization of 33.58B. The stock trades at a price-to-earnings (P/E) ratio of -102.81.

On 2026-01-21, Natera(NTRA) stock traded between a low of $234.04 and a high of $255.38. Shares are currently priced at $245.38, which is +4.8% above the low and -3.9% below the high.

Natera(NTRA) shares are trading with a volume of 1.42M, against a daily average of 1.35M.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

NTRA News

TipRanks 12h
Natera announces publication of validation study for Latitude tissue-free assay

Natera (NTRA) announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay, or tfMR...

Simply Wall St 4d
Assessing Natera Valuation After AI Oncology Advances And Strong 2025 Growth Guidance

Natera (NTRA) is back in focus after issuing guidance that points to a 39% year over year jump in Q4 revenue, projected 35% full year 2025 revenue growth, and f...

Assessing Natera Valuation After AI Oncology Advances And Strong 2025 Growth Guidance
Nasdaq 5d
First Week of NTRA March 20th Options Trading

Investors in Natera Inc (Symbol: NTRA) saw new options begin trading this week, for the March 20th expiration. At Stock Options Channel , our YieldBoost formula...

First Week of NTRA March 20th Options Trading

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

More NTRA News

Simply Wall St 5d
AI-Enhanced Signatera Upgrade And NVIDIA Deal Could Be A Game Changer For Natera

Natera has recently reported strong 2025 revenue growth, unveiled an AI-driven, multi-modal upgrade to its Signatera MRD test, and expanded its fetal genetic te...

AI-Enhanced Signatera Upgrade And NVIDIA Deal Could Be A Game Changer For Natera
Simply Wall St 7d
Is It Too Late To Consider Natera After Its Strong 1-Year Share Price Run?

If you are wondering whether Natera's current share price lines up with its underlying value, you are not alone. This article is built to help you connect the d...

Is It Too Late To Consider Natera After Its Strong 1-Year Share Price Run?

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.